Description of mutations and functoin of a gene implicated in the development of Fanconi anemia and predisposition to ca

June 1, 2007

An international research consortium, which included the participation of the Mutagènesi Group from the UAB, has made outstanding progress in the study of Fanconi anaemia. They have described the function and range of possible mutations of the gene implicated in this disease that affects functions like nerve and skeletal development, blood cell formation and predisposition to cancer.

This discovery will aid in detecting the defective gene that causes Fanconi anaemia, which is fundamental in prenatal diagnosis and even pre-implantation diagnosis where the objective is to select an embryo that is compatible with a transplant donor. Furthermore, identification of the responsible gene is indispensable for the future application of gene therapy.

The researchers have studied the function and mutational spectrum of the FANCD2 gene, one of thirteen genes implicated in Fanconi anaemia. The result is a step forward in the knowledge of the genetics and molecular biology of this disease which, although rare, is of important biomedical interest because the proteins that are implicated with it are also associated with different vital functions and cancer suppression. The work covers the molecular studies of all the D2 Fanconi patients (those affected by the Fanconi anaemia that present alternations of this gene) known around the world.

A more severe and rapid variant

This work also compared FANCD2 patients with 754 patients with FANCA, FANCC and FANCG, which are the more prevalent variants worldwide. The results indicate that the Fanconi D2 patients’ symptoms (clinical phenotype) are more severe than the others.

This is due to the vital function of the FANCD2 gene in the maintenance of the stability of the genome and in the development and function of the multiple organs and tissues, such as the formation of white blood cells, platelets and other elements of the blood (Fanconi D2 patients have a dysfunction in the production of blood in the medulla starting at 2.4 years old on average), neuronal development (89% of the Fanconi D2 patients suffer from microcephalia) or the formation of skeletal tissue (72% of the Fanconi D2 patients present skeletal malformations). In addition, the progression of the disease is more rapid in Fanconi D2 patients resulting in the need for early transfusions for survival and transplants when there is a compatible donor.

Differences with animal models

On the other hand, the research shows that the mutations do not totally eliminate the FANCD2 gene function, but cause a low level of expression of the FANCD2 protein. These results indicate that in humans, as opposed to what was observed in mice, the total absence of the FANCD2 protein is impossible (without this protein the embryo will not develop), and underline the findings that animal models do not always reflect the clinical phenotype of the disease.

A consortium of 13 European and North American laboratories and hospitals performed the research, which included the group directed by Dr. Jordi Surrallés of the Departament de Genètica i de Microbiologia (Department of Genetics and Microbiology) of the UAB and assigned to the Centro de Investigaciones Biomédicas en Red de Enfermedades Raras del Instituto de Salud Carlos III (CIBER-ER) (Biomedical Research Centre for Rare Diseases of the Carlos III Health Institute network). The American Journal of Human Genetics published the results in their May edition.

This study, together with others published by Dr. Surrallés’ team complements a model study described in the May edition of the review Cell Cycle that relates the genetic base of the disease with its clinical heterogeneous progression. This model is based on the fact that the patients with a total absence of FANCA protein, whose main function is to activate FANCD2 protein, have a milder clinical phenotype than FANCD2 patients. In turn, these are milder than patients with FANCD1/BRCA2, a gene that acts directly on a DNA level and promotes repairs in cases of genetic mutations.

Source: Universitat Autònoma de Barcelona

Explore further: Rare childhood disease linked to major cancer gene

Related Stories

Rare childhood disease linked to major cancer gene

December 1, 2016
A team of researchers led by a University of Rhode Island scientist has discovered an important molecular link between a rare childhood genetic disease, Fanconi anemia, and a major cancer gene called PTEN. The discovery improves ...

Gene controls three different diseases

April 25, 2013
An international research consortium led by the Universitat Autònoma de Barcelona (UAB), the CIBERER and the University of Wurzburg (Germany) has discovered a gene that can cause three totally different diseases, depending ...

Rare Diseases: De novo mutation leading to Fanconi Anemia identified

December 22, 2015
An international team of researchers has established the cause of rare syndrome consistent with Fanconi Anemia: a de novo mutation in a so called RAD51 gene, which is responsible for repairing damages in the DNA. Fanconi ...

Study identifies new gene mutation associated with defective DNA repair and Fanconi anemia

July 10, 2017
Fanconi anemia is a rare genetic disease characterized by hematologic symptoms that include low platelet count and unusually large red blood cells. Mutations in nearly 20 genes have been identified as causative for Fanconi ...

Rare genetic disease offers insight into common cancers

September 4, 2012
Fanconi anemia is a recessive genetic disorder affecting 1 in 350,000 babies, which leaves cells unable to repair damaged DNA. This lack of repair puts Fanconi anemia patients at high risk for developing a variety of cancers, ...

Team identifies new function of genes linked to Fanconi anemia and certain types of cancer

May 3, 2016
Researchers from UT Southwestern Medical Center have identified an important new function of genes in the Fanconi anemia pathway—a finding that could have implications for development of new therapies to treat this disorder ...

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.